套细胞淋巴瘤
生物
癌症的体细胞进化
癌症研究
外显子组测序
转录组
恶性肿瘤
下调和上调
细胞周期蛋白D1
基因组不稳定性
淋巴瘤
遗传学
细胞周期
突变
基因
DNA损伤
免疫学
DNA
基因表达
作者
Shuhua Yi,Yuting Yan,Meiling Jin,S. Bhattacharya,Yi Wang,Yiming Wu,Lu Yang,Eva Giné,Guillem Clot,Lu Chen,Ying Yu,Dehui Zou,Jun Wang,An T. Phan,Rui Cui,Fei Li,Qi Sun,Qiong-Li Zhai,Tingyu Wang,Zhen Yu
摘要
Mantle cell lymphoma (MCL) is a phenotypically and genetically heterogeneous malignancy in which the genetic alterations determining clinical indications are not fully understood. Here, we performed a comprehensive whole-exome sequencing analysis of 152 primary samples derived from 134 MCL patients, including longitudinal samples from 16 patients and matched RNA-Seq data from 48 samples. We classified MCL into 4 robust clusters (C1-C4). C1 featured mutated immunoglobulin heavy variable (IGHV), CCND1 mutation, amp(11q13), and active B cell receptor (BCR) signaling. C2 was enriched with del(11q)/ATM mutations and upregulation of NF-κB and DNA repair pathways. C3 was characterized by mutations in SP140, NOTCH1, and NSD2, with downregulation of BCR signaling and MYC targets. C4 harbored del(17p)/TP53 mutations, del(13q), and del(9p), and active MYC pathway and hyperproliferation signatures. Patients in these 4 clusters had distinct outcomes (5-year overall survival [OS] rates for C1-C4 were 100%, 56.7%, 48.7%, and 14.2%, respectively). We also inferred the temporal order of genetic events and studied clonal evolution of 16 patients before treatment and at progression/relapse. Eleven of these samples showed drastic clonal evolution that was associated with inferior survival, while the other samples showed modest or no evolution. Our study thus identifies genetic subsets that clinically define this malignancy and delineates clonal evolution patterns and their impact on clinical outcomes.
科研通智能强力驱动
Strongly Powered by AbleSci AI